NVS

Novartis AG Form 6-K Summary: First Quarter 2005

Business Context and Reporting Period

This Form 6-K, dated April 22, 2005, reports the unaudited financial results for Novartis AG for the first quarter ended March 31, 2005. The filing incorporates the adoption of new International Financial Reporting Standards (IFRS) effective January 1, 2005, including changes to share-based compensation (IFRS 2), business combinations (IFRS 3), and intangible assets (IAS 38). Comparative 2004 figures are presented on a pro forma basis to ensure comparability.

Key Financial Metrics

Material Changes vs. Prior Period

• Sales Growth: Group net sales rose 11% (7% in local currencies), driven by volume increases (+7 percentage points), currency benefits (+4 percentage points), and acquisitions (+1 percentage point), partially offset by net price decreases (-1 percentage point).
• Divisional Performance:
  • Pharmaceuticals: Sales up 11% (8% lc) to $4.8 billion. Excluding a one-time $62 million accounting adjustment for US sales rebates, sales would have grown 13%. Oncology sales surged 26%.
  • Sandoz: Sales up 12% (7% lc) to $803 million, aided by European growth and 2004 acquisitions (Durascan, Sabex).
  • Consumer Health: Sales up 9% (6% lc) to $1.7 billion, supported by Medical Nutrition and Animal Health.
• Profitability: Operating income grew faster than sales (16% vs 11%), improving the margin by 1 percentage point. This was boosted by a $135 million gain from the divestment of the Cibacen product in Europe.
• Balance Sheet: Equity decreased by $1.8 billion to $29.5 billion due to a $2.1 billion dividend payment, $0.5 billion in share repurchases, and $0.7 billion in translation losses, despite strong net income.

Guidance, Outlook, and Risks

Outlook: Management reaffirmed its 2005 outlook, anticipating high single-digit net sales growth for the Group and Pharmaceuticals in local currencies. The company expects to deliver record sales and record earnings on a comparable basis, barring unforeseen events.

Strategic Initiatives: Integration planning for the acquisitions of Hexal AG and Eon Labs is on track, expected to close in the second half of 2005. These deals aim to make Sandoz the global leader in generics with pro forma 2004 sales of $5.1 billion.

Risks and Contingencies:

• Regulatory: Novartis is in discussions with the FDA regarding a "black box" warning for Elidel and Protopic; the company disputes the necessity of this warning. Additionally, a generic company filed an ANDA for Diovan, though Novartis notes the generic cannot market until at least 2012 due to patent protections.
• Competition: Increased competition in the US generics market and pricing pressures in certain regions.
• Forward-Looking Statements: Results depend on clinical trial outcomes, regulatory approvals, and the ability to maintain intellectual property protection.

Investor Verification Checklist

• Accounting Adjustments: Verify the impact of the $62 million one-time adjustment to Pharmaceuticals sales regarding US sales rebates and the $135 million gain from the Cibacen divestment on operating income.
• IFRS Adoption: Review the reconciliation between IFRS and US GAAP figures, particularly regarding share-based compensation and goodwill amortization, as these significantly affect reported net income and equity.
• Acquisition Timeline: Monitor the regulatory approval status and closing dates for the Hexal and Eon Labs acquisitions, which are critical to the Sandoz growth strategy.
• Product Pipeline: Track the status of key pipeline assets, including Exjade (iron chelator), Aclasta (Paget's disease), and FTY720 (multiple sclerosis), as well as the FDA's final decision on the Elidel warning label.
• Cash Flow Drivers: Note that the 88% increase in operating cash flow was largely driven by a timing difference in withholding tax payments related to dividends, which may not be sustainable in subsequent quarters.